🏗️ The company will add two 1,200L bioconjugation manufacturing suites.
💼 This expansion aims to create around 200 new jobs by 2028.
📈 The suites will double their capacity for antibody-drug conjugates.
🌱 Lonza emphasizes sustainability in this new infrastructure.
Introduction:
This article discusses Lonza’s recent decision to enhance its bioconjugation manufacturing capabilities in Visp, Switzerland, aiming to meet the growing demand for antibody-drug conjugates (ADCs) and other bioconjugates in the pharmaceutical market.
- Lonza will add two multipurpose 1,200L manufacturing suites at its Visp site, which will significantly increase capacity for bioconjugation processes.
- The new facilities will create approximately 200 jobs and are expected to be operational by 2028.
- The expansion will mainly support the development and commercial supply of ADCs and other bioconjugates, enhancing Lonza’s position as a contract development and manufacturing organization (CDMO).
- Sustainability is a key focus, with the new suites being designed to reduce energy consumption and waste, including a 90% reduction in cytotoxic waste.
- Since 2006, Lonza has produced over 1,000 cGMP batches for more than 70 programs, demonstrating its extensive experience and integrated approach in the bioconjugate manufacturing sector.
Conclusion:
Lonza’s investment in expanding its bioconjugation capabilities is a strategic response to the increasing commercialization of ADCs, aligning with market demand while adhering to sustainability principles. This development reinforces Lonza’s commitment to providing integrated manufacturing solutions and supports its clients in advancing their therapeutic pipelines.
